

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京健康(控股)有限公司
Beijing Health (Holdings) Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2389)

PROFIT WARNING

This announcement is made by Beijing Health (Holdings) Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the period ended 30 June 2024 and the information currently available to the Company, it is expected that loss attributable to the owners of the Company of the Group for the period ended 30 June 2024 will increase by approximately HK\$40,000,000 as compared with the corresponding period in 2023. During the current period, the Group’s day-to-day operations remained relatively stable and the main reasons for the increase in loss attributable to the owners of the Company are as follows:

- (1) Exchange losses of approximately HK\$12,400,000 of other receivables and investments in associates of the Group denominated in CAD were recorded for the current period due to the depreciation of CAD, and exchange gains of approximately HK\$10,110,000 were recorded for the corresponding period of previous year;
- (2) The share price of listed associates held by the Group decreased during the period, the Group performed an impairment assessment for the investment and provision for impairment during the period increased by approximately HK\$5,250,000;
- (3) As the debt investment of the Group in Ovation real estate project in Canada was completed at the beginning of the current period, the interest income recognized during the period decreased by approximately HK\$5,130,000; and

- (4) The loss attributable to joint ventures recognized for the period increased by HK\$4,980,000, which is mainly due to the increase in interest expenses of joint ventures resulted from the increase in interest rates.

As at the date of this announcement, the Company is still in the process of finalizing its interim results for the six months ended 30 June 2024. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group, and may be subject to final revisions and other review adjustments on impairment of assets (if any), final share of profits/losses of associates, fair value of investment properties during the review process. The details of the interim results of the Group for the six months ended 30 June 2024 will be disclosed in the interim results announcement of the Company, which is expected to be published on 29 August 2024.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Beijing Health (Holdings) Limited
Zhu Shi Xing
Chairman

Hong Kong, 9 August 2024

As at the date of this announcement, the Board comprises five Executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao, Mr. Siu Kin Wai and Mr. Wang Zheng Chun and three Independent Non-Executive Directors, namely Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin and Mr. Zhang Yun Zhou.